Apogee Therapeutics(NASDAQ) APGE

Apogee Therapeutics, Inc. makes medicine for skin and lung diseases. These treatments help people with painful rashes or breathing problems. Its shots are designed to be taken only twice a year.

A Pipeline of Advanced Biologics

• Zumilokibart: Injectable lab-made protein targeting IL-13 for atopic dermatitis, a common type of eczema, and asthma; designed for dosing every three to six months.
• APG808: Long-acting antibody targeting IL-4R alpha for chronic obstructive pulmonary disease, a chronic lung condition, and asthma.
• APG279: Combined therapy of zumilokibart and APG990 for patients suffering from moderate-to-severe eczema.
• APG273: Combination of zumilokibart and APG333 intended for the treatment of asthma and lung disease.
• APG531: New research program directed at the IL-31 receptor to treat various inflammatory conditions.

Strategic Partnerships and Merger News

• Entered a merger agreement on June 18, 2026, to be acquired by AbbVie for $135.11 per share in cash.
• Secured $100.0 million in upfront funding from Blackstone Life Sciences in May 2026 through a revenue share agreement for zumilokibart.
• Signed an antibody discovery and license agreement with Paragon in June 2026 to develop the APG531 program.
• Raised $377.4 million in net proceeds through a public offering of 5,750,000 shares of common stock in March 2026.

Engineering Longer-Lasting Treatments

Apogee focuses on engineering antibodies with an extended half-life, which is the amount of time a medicine remains active in the body. This approach aims to reduce the frequency of injections for patients from every two weeks to as few as two to four times per year.

Losses and Liquidity in 2026

• Net loss was $160.0 million for the six-month period ended June 30, 2026.
• Research and development expenses reached $128.1 million for the six-month period ended June 30, 2026, an increase of $26.0 million from 2025.
• Cash, cash equivalents, and marketable securities totaled $1.3 billion as of June 30, 2026.
• Accumulated deficit reached $721.7 million at the end of the second quarter of 2026.
• General and administrative expenses were $46.3 million for the six-month period ended June 30, 2026.

The Company Evolution

Apogee has progressed from a private startup to a clinical-stage biotechnology firm with multiple candidates in human trials. Its recent agreement to be acquired by AbbVie marks a transition from independent drug development to integration with a global pharmaceutical leader.